Bugs and Drugs Primer (Global)
The new Bugs and Drugs primer covers key microbiology and pharmacology concepts as well as case-based exercises on management of Gram positive and Gram negative organisms; to provide a foundation for stewardship principles and practice along with many other high yield concepts.
Content in this section is available through (7) eLearning modules. The 7 modules include:
Module 1: Foundations of Microbiology - Susceptibility Testing and Rapid Diagnostics
Module 2: Foundation of Pharmacology
Module 3: Foundations - Case One
Module 4: Foundations - Case Two
Module 5: Foundations - Case Three
Module 6: Foundations - Case Four
Module 7: Foundations - Case Five
Target Audience
Fellows/Trainees in Antimicrobial Stewardship Programs
Learning Objectives
Bugs (Microbiology) Learning Objectives:
- Describe methods, use and limitations of culture and non-culture based rapid diagnostic tests most relevant to the practice of antimicrobial stewardship
- Describe commonly utilized methods of antimicrobial susceptibility testing in the clinical microbiology lab and explain benefits and limitations of each method
- Describe principles of MIC interpretation and apply practical CLSI data effectively when considering a case
- Discuss rapid diagnostic and resistance/susceptibility testing principles most important to the major bacterial pathogens (S.aureus, Enterobacterales, Pseudomonas, Enterococcus) relevant to stewardship
Drugs (Pharmacology) Learning Objectives:
- Describe general concepts and principles of the pharmacokinetics/pharmacodynamics (PK/PD) of antimicrobials
- Identify PK/PD indices of specific antimicrobials most associated with bacterial eradication.
- Characterize how drug exposure impacts antimicrobial efficacy, toxicity and resistance in order to design appropriate antimicrobial regimens
- Identify clinical circumstances favoring the performance of antimicrobial Therapeutic Drug Monitoring (TDM) (e.g. available drug assay, unpredictable drug dose-exposure relationship, clear relationship between drug exposure and efficacy and/or toxicity)
- Apply PK/PD data, target indices, and therapeutic drug monitoring to the design of appropriate antimicrobial regimens for patients with altered pharmacokinetics and/or in special populations